Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Heart Failure: A Class Review of Pharmacotherapy.

Shah A, Gandhi D, Srivastava S, Shah KJ, Mansukhani R.

P T. 2017 Jul;42(7):464-472.

PMID:
28674474
2.

Angiotensin II receptor blockers induce autophagy in prostate cancer cells.

Woo Y, Jung YJ.

Oncol Lett. 2017 May;13(5):3579-3585. doi: 10.3892/ol.2017.5872. Epub 2017 Mar 17.

3.

When less is more - efficacy with less toxicity at the ED50.

Dimmitt S, Stampfer H, Martin JH.

Br J Clin Pharmacol. 2017 Jul;83(7):1365-1368. doi: 10.1111/bcp.13281. Epub 2017 Apr 6. No abstract available.

PMID:
28387051
4.

Macrophage activation and polarization in post-infarction cardiac remodeling.

Gombozhapova A, Rogovskaya Y, Shurupov V, Rebenkova M, Kzhyshkowska J, Popov SV, Karpov RS, Ryabov V.

J Biomed Sci. 2017 Feb 7;24(1):13. doi: 10.1186/s12929-017-0322-3. Review.

5.

Effect of telmisartan and enalapril on ventricular remodeling and kidney prognosis of patients with coronary artery disease complicated with diabetic nephropathy.

Hou Y, Zhang F, Liu Z, Su S, Wu X, Wang Z.

Exp Ther Med. 2017 Jan;13(1):131-134. doi: 10.3892/etm.2016.3933. Epub 2016 Nov 29.

6.

Higher medication doses in heart failure?

McCormack J, McAlister FA, Kolber MR.

Can Fam Physician. 2017 Jan;63(1):e20. Review. No abstract available.

7.

Sacubitril/valsartan in heart failure: latest evidence and place in therapy.

Kaplinsky E.

Ther Adv Chronic Dis. 2016 Nov;7(6):278-290. Epub 2016 Oct 19. Review.

8.
9.

Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus.

Bahtiyar G, Gutterman D, Lebovitz H.

Curr Diab Rep. 2016 Nov;16(11):116. Review.

10.

Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation.

Upshaw JN, Konstam MA, Klaveren Dv, Noubary F, Huggins GS, Kent DM.

Circ Heart Fail. 2016 Aug;9(8). pii: e003146. doi: 10.1161/CIRCHEARTFAILURE.116.003146.

PMID:
27514751
11.

Critical Questions about PARADIGM-HF and the Future.

Chen CH.

Acta Cardiol Sin. 2016 Jul;32(4):387-96. Review.

12.

Hyperuricemia, Cardiovascular Disease, and Hypertension.

Kuwabara M.

Pulse (Basel). 2016 Apr;3(3-4):242-52. doi: 10.1159/000443769. Epub 2016 Mar 12. Review.

13.
14.

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

Dézsi CA.

Am J Cardiovasc Drugs. 2016 Aug;16(4):255-66. doi: 10.1007/s40256-016-0165-4. Review.

15.

An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease.

Elkahloun AG, Hafko R, Saavedra JM.

Alzheimers Res Ther. 2016 Jan 28;8:5. doi: 10.1186/s13195-015-0167-5.

16.

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.

Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR.

Eur J Heart Fail. 2015 Oct;17(10):1057-65. doi: 10.1002/ejhf.402. Epub 2015 Oct 12.

17.

Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker.

Forsdyke DR.

BMC Res Notes. 2015 Jun 9;8:227. doi: 10.1186/s13104-015-1215-8.

18.

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.

Anker SD, Kosiborod M, Zannad F, Piña IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P.

Eur J Heart Fail. 2015 Oct;17(10):1050-6. doi: 10.1002/ejhf.300. Epub 2015 Jun 16.

19.

A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats.

Chang SA, Lim BK, Lee YJ, Hong MK, Choi JO, Jeon ES.

J Korean Med Sci. 2015 May;30(5):559-68. doi: 10.3346/jkms.2015.30.5.559. Epub 2015 Apr 15.

20.

In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study.

Ho TW, Tsai YJ, Ruan SY, Huang CT, Lai F, Yu CJ; HINT Study Group.

PLoS One. 2014 Dec 9;9(12):e114866. doi: 10.1371/journal.pone.0114866. eCollection 2014.

Supplemental Content

Support Center